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Neuroblastoma is the most common extra-cranial solid tumor in childhood; and patients in stage IV of
the disease have a high propensity for tumor recurrence. Retinoid therapy has been utilized as a means to
induce differentiation of tumor cells and to inhibit relapse. In this study, the expression of a common
neuronal differentiation marker [neuroﬁlament M (NF-M)] in human SK-N-SH neuroblastoma cells
treated with 10 μM all-trans retinoic acid (ATRA) showed signiﬁcantly increased expression in ac-
cordance with reduced cell number. This was accompanied by an increase in MitoSOX and DCFH2 oxi-
dation that could be indicative of increased steady-state levels of reactive oxygen species (ROS) such as
O2 and H2O2, which correlated with increased levels of MnSOD activity and immuno-reactive protein.
Furthermore PEG-catalase inhibited the DCFH2 oxidation signal to a greater extent in the ATRA-treated
cells (relative to controls) at 96 h indicating that as the cells became more differentiated, steady-state
levels of H2O2 increased in the absence of increases in peroxide-scavenging antioxidants (i.e., glu-
tathione, glutathione peroxidase, and catalase). In addition, ATRA-induced stimulation of NF-M at 48 and
72 h was enhanced by decreasing SOD activity using siRNA directed at MnSOD. Finally, treatment with
ATRA for 96 h in the presence of MnSOD siRNA or PEG-catalase inhibited ATRA induced increases in NF-
M expression. These results provide strong support for the hypothesis that changes in steady-state levels
of O2 and H2O2 signiﬁcantly contribute to the process of ATRA-induced differentiation in neuro-
blastoma, and suggest that retinoid therapy for neuroblastoma could potentially be enhanced by redox-
based manipulations of superoxide metabolism to improve patient outcome.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Children diagnosed with high-risk neuroblastoma are highly
susceptible to recurrent tumors, even after initial treatments such
as surgery, radiation and/or chemotherapy. Retinoids are a suc-
cessful therapeutic option for these patients. All-trans retinoic acid
(ATRA; tretinoin) and 13-cis-retinoic acid (13-cis RA; isotretinoin),
metabolites of Vitamin A, not only stimulate differentiation [34],
but also inhibit cellular proliferation, induce apoptosis [2], and
promote cell cycle arrest [9]. Although 13-cis RA is currently ad-
ministered clinically for neuroblastoma, ATRA is the ultimate
metabolite in vivo and one of the most potent differentiation in-
ducers for human neuroblastoma in vitro [37]. The “cis” isoform
likely has effects independent of ATRA; however, anti-proliferativeB.V. This is an open access article u
.K. Kiningham).capabilities are suggested to be due to isomerization to the “trans”
form in human neuroblastoma cells [44]. Despite its ability to
differentiate cancer cells, the drawback of long-term retinoid
treatment is that patients acquire resistance to chemotherapeutic
drugs such as adriamycin and cisplatin [11,20]. Nonetheless, re-
tinoids are a much safer, less toxic alternative. Studies indicate
retinoids not only stimulate the production of reactive oxygen
species (ROS), but also upregulate antioxidant defense pathways
during neuroblastoma differentiation [27,35,36]. Nonetheless, to
our knowledge, this is the ﬁrst study performing a comprehensive
analysis of the antioxidant response system (ROS and anti-
oxidants) during all-trans retinoic acid- (ATRA) induced differ-
entiation of a neuroblastoma cell line (SK-N-SH). Given the ther-
apeutic beneﬁts of retinoid treatment for differentiating neuro-
blastoma cells it is necessary to further characterize retinoids'
inﬂuence on speciﬁc signaling pathways and identify the ROS re-
sponsible for the anti-proliferative activity in order to develop ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The current study was designed to determine if the mi-
tochondrial manganese containing superoxide dismutase enzyme
(MnSOD) was essential to ATRA-mediated differentiation in the
SK-N-SH neuroblastoma model. The results showed 10 μM ATRA
induced a signiﬁcant increase in the differentiation marker, neu-
roﬁlament M (NF-M) prior to induction of MnSOD activity in
neuroblastoma cells. Furthermore suppressing the induction of
MnSOD activity using an siRNA, enhanced NF-M expression in the
presence of ATRA for 48 or 72 h. Finally polyethene glycol con-
jugated catalase (PEG-CAT) as well as siRNA against MnSOD were
both able to suppress ATRA-induced increases in NF-M protein at
96 h of treatment with retinoids. Taken together, these data sup-
port the hypothesis that superoxide is essential for inducing the
differentiation of neuroblastoma cells in the early phase (0–72 h)
of ATRA treatment, whereas both superoxide and hydrogen per-
oxide play a role in modulating levels of NF-M at 96 h.2. Materials and methods
2.1. Cell culture and treatment
For all experiments, the human neuroblastoma cell line (SK-N-
SH) obtained from the American Type Culture Collection (Mana-
ssas, VA) was maintained in minimal essential medium (MEM;
Sigma, St. Louis, MO) supplemented with 10% heat-inactivated
bovine serum (Invitrogen, Carlsbad, CA), 1% penicillin/streptomy-
cin/neomycin (Invitrogen), 1% non-essential amino acids (Invitro-
gen), and 1 mM sodium pyruvate (Sigma-Aldrich). Cells were
grown at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
Dimethyl sulfoxide (DMSO) and all-trans retinoic acid (ATRA) were
obtained from Sigma-Aldrich. DMSO (0.05%) treatment served as
the control and followed the same regimen as ATRA treatment
(10 μM). The concentration of ATRA used is consistent with pre-
vious reports to induce differentiation in this cell type [30,37].
Representative pictures were obtained by use of an Olympus
CKX41 Inverted Microscope with Camera and MicroSuite V Ima-
ging software (10 magniﬁcation).
2.2. Growth rate analysis
On day one, cells were plated at a density of 2103 cells/cm2.
On day two, 2 plates were counted as the 24 h control. Two plates
per treatment were counted and averaged each subsequent day for
the duration of the experiment. ATRA-containing culture media
was replenished every 48 h. The data are represented as the
average log of cell numbers vs. time (hrs).
2.3. Western blot analysis
Cells were plated 24 h prior to initiating treatments at a density
of 1–5104 cells/cm2. Whole cell lysates were collected via
scraping in cold phosphate buffered saline (PBS; 137 mM sodium
chloride, 3 mM potassium chloride, 1 mM potassium phosphate
monobasic, 10 mM sodium phosphate dibasic; pH 7.4) and cen-
trifuged at 1 500 rpm5 min at 4 °C. Pellets were subjected to at
least one freeze-thaw cycle at 80 °C and resuspended in HALT
protease inhibitor cocktail (Thermo Scientiﬁc, Rockford, IL) to be
analyzed via SDS-PAGE. Proteins were transferred to nitrocellulose
membranes and transfer efﬁciency was assessed by staining with
0.1% Ponceau S. Membranes were incubated overnight with pri-
mary antibodies neuroﬁlament-M (1: 2000; Invitrogen), or gly-
ceraldehye 3-phosphate dehydrogenase (GAPDH) (1:50,000; Tre-
vigen, Gaithersburg, MD), followed by a horseradish peroxidase
conjugated secondary antibody (1: 3000; Santa Cruz, Santa Cruz,CA). Detection of antibody-protein interactions were made via the
enhanced chemiluminescence system (Amersham Biosciences,
Piscataway, NJ). All speciﬁc protein expression was normalized to
levels of GAPDH and reported as fold change vs. control (CON:
DMSO treated cells).
2.4. 5(and-6)-chloromethyl-2′,7′-dichlorodihydro-ﬂuorescein diace-
tate (DCF) and MitoSOX ﬂuorescence
Oxidant generation was assessed by monitoring the oxidation
of 5(and-6)-chloromethyl-2′,7′-dichlorodihydro-ﬂuorescein dia-
cetate, acetyl ester (CM-H2DCFDA, “DCFH2”, Invitrogen) and Mi-
toSOX™ Red (Invitrogen). For DCFH2 oxidation assays, SK-N-SH
cells were plated 48 h before initiation of treatments at a density
of 5104 cells/cm2. At the completion of treatments (or siRNA
transfections), cells were washed 1 with serum free MEM (SF-
MEM) and incubated in the presence of 2.5 mM CM-H2DCFDA in
SF-MEM for 5 min at 37 °C, 5% CO2. Cells cultured in parallel were
incubated with 0.1–10 mM H2O2 after DCFH2 incubation as a po-
sitive control. All cells were then washed 1 with PBS, trypsi-
nized, and collected for FACS analysis (excitation at 493 nm,
emission at 525 nm). Carboxy-DCFDA (DCF, Molecular Probes,
Eugene, OR) (2.5 mM) is an oxidation insensitive dye that was used
as a control for changes in uptake, ester cleavage, and efﬂux so that
changes in ﬂuorescence seen with the oxidation-sensitive dye
could be directly attributed to changes in steady-state levels of
DCFH2 oxidation. Median ﬂuorescence intensity of 10,000 cells
was analyzed in each sample. For MitoSOX oxidation assays, cells
were plated 48 h before initiation of treatments at a density of
8104 cells/cm2. At the completion of treatments, cells were
washed with PBS and incubated in the presence of 5 μM MitoSOX
for 10 min at 37 °C, 5% CO2. Cells cultured in parallel were in-
cubated with rotenone (1–200 mM) and MitoSOX (described
above) as a positive control. Fluorescence was then measured
(excitation at 510 nm, emission at 580 nm) at 10 and 40 min. The
relative change in ﬂuorescence between 10 and 40 min is ex-
pressed as the fold change of treated vs. control. All absorbance
values were also normalized according to protein content.
2.5. Glutathione (GSH) levels
Cells were plated at a density of 3104 cells/cm2. At the
completion of treatments, whole cell lysates were collected via
scraping cells in cold PBS and centrifuging at 2000 rpm for 5 min
at 4 °C. The resulting cell pellet was resuspended in potassium
phosphate buffer (50 mmol/L, pH 7.8) and aliquots were taken for
quantiﬁcation of protein concentration. Sulfosalicylic acid was
added to the remaining solution at a concentration required to
achieve a ﬁnal value of 5%. Samples were incubated on ice for at
least 10 min, centrifuged at 2000 rpm for 5 min at 4 °C, and su-
pernatants were saved and stored immediately at 80 °C. Levels
of GSH and GSSG were distinguished by adding a mixture of
2-vinylpyridine and triethanolamine (TEA) (2:1), incubated for
30 min, and assayed as described by Grifﬁth and Anderson [3,15].
All values were normalized according to protein content and re-
ported as fold change vs. control.
2.6. Glutathione peroxidase and catalase activity
Cells were plated at a density of 3104 cells/cm2. At the
completion of treatments, whole cell lysates were collected via
scraping cells in cold PBS and centrifuging at 2000 rpm for 5 min
at 4 °C. The resulting cell pellet was stored at 80 °C until being
resuspended in potassium phosphate buffer (50 mmol/L, pH 7.8)
with DETAPAC (1.34 mM diethylenetriaminepentaacetic acid). We
utilized an adaptation of methods by Zhang et al. [47] by
Fig. 1. ATRA promoted differentiated morphology, increased NF-M expression, and decreased number of the SK-N-SH cells. (A) Representative images from SK-N-SH cells
treated with ATRA (10 μM) for 24 h, 48 h, and 2 wks. Arrows denote neurite formation. (B) Western Blot analysis of neuroﬁlament M (NF-M) expression after treatment with
ATRA (10 μM) for 24, 48, 72, and 96 h. n¼5. *po0.05, signiﬁcant difference between CON and ATRA at each time point. †po0.05, signiﬁcant difference between ATRA 72,
96 h vs. 24, 48 h. Kruskal–Wallis One way ANOVA on Ranks; Student-Newman–Keuls. Results are expressed as fold changes vs. 24 h CON7SEM. (C) Cell number after
treatment with ATRA (10 μM) for 24, 48, 72, and 96 h. n¼4. *po0.05, signiﬁcant difference vs. 24 h CON; †po0.05, signiﬁcant difference between ATRA and CON at
respective time point. One way ANOVA; Student-Newman–Keuls. Results are expressed as changes in log cell number7SEM.
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mediately analyzing spectrophotometrically for 90 s at 240 nm.
The change in absorbance within 60 s was recorded to reﬂect
catalase activity in each sample. Glutathione peroxidase (GPx)
activity was determined according to the method of [21]. Brieﬂy,
samples were added to a solution of phosphate buffer (100 mM
Tris/HCl pH 7.6, 5 mM EDTA, 1 mM sodium azide), reduced glu-
tathione (3 mM), glutathione reductase (600 U/mL), and NADPH
(0.1 mM); then incubated at 30 °C for 5 min. The enzymatic reac-
tion was started by adding H2O2 (ﬁnal concentration of 1.5 mM)
and evaluated by measurement of NADPH consumption at 340 nm.
All values were normalized according to protein content and re-
ported as milliunits (munits)/mg protein.
2.7. MnSOD activity
Activity of SOD was measured in whole cell lysates using an
indirect competition assay between SOD and the indicator com-
pound, nitroblue tetrazolium, for superoxide produced by xan-
thine/xanthine oxidase [39]. The activity of the MnSOD isoform
was measured in the presence of sodium cyanide, an inhibitor of
copper zinc SOD. The data were normalized to protein content as
measured by the Lowry colorimetric assay utilizing bovine serum
albumin as a control and reported as units/mg protein.
2.8. SOD2 siRNA treatment
Small interfering RNA against the human SOD2 gene was used
to silence expression of MnSOD. Cells were plated 24 h before
initiation of treatments at a density of 3104 cells/cm2. Cells were
then rinsed with serum free MEM (SF-MEM) prior to transfection
with either 100 nM SOD2 small interfering RNA (SOD2 siRNA)
(ON-TARGET plus SMART pool, Dharmacon Inc, Chicago, IL) or
Control siRNA (Ctrl siRNA) (siCONTROL non-targeting siRNA,
Dharmacon Inc, Chicago, IL) using Hiperfect transfection reagent
(Qiagen, Valencia, CA). Transfected cells were treated with either
vehicle or ATRA (10 μM) 24 h later. Following treatments, whole
cell lysates were collected via scraping in cold PBS, and centrifuged
at 1500 rpm5 min at 4 °C. Pellets were subjected to at least one
freeze-thaw cycle at 80 °C and resuspended in HALT protease
inhibitor cocktail (Thermo Scientiﬁc, Rockford, IL) to be analyzed
for protein expression (SDS-PAGE), or in DETAPAC buffer for
MnSOD activity.
2.9. Statistical analysis
All experiments were replicated at least in triplicate and values
reported as mean 7S.E.M. When comparing two means, Student's
t-test was used, po0.05. When comparing multiple means, the
results were analyzed either by one way ANOVA or one way AN-
OVA on ranks followed by the Student Newman–Keuls test at a
95% conﬁdence interval.Fig. 2. ATRA modulated DCFH2 oxidation and MitoSOX oxidation in SK-N-SH cells.
MitoSOX (n¼5) and DCF (n¼4) ﬂuorescence of SK-N-SH cells after treatment with
ATRA (10 μM) for 24, 48, 72, and 96 h. MitoSOX: *po0.05 vs. CON. DCF: †po0.05
vs. CON. T-test performed for each time point vs. CON. Results are expressed as fold
changes vs. CON at each time point7SEM.3. Results
3.1. ATRA promoted differentiated morphology, increased NF-M ex-
pression, and slowed proliferation of the SK-N-SH cells
The common mechanism by which retinoids antagonize car-
cinogenesis is by inducing differentiation and suppressing the
ability of the cells to proliferate. To validate these therapeutic ef-
fects, SK-N-SH neuroblastoma cells were treated with 10 uM ATRA
and cellular morphology, growth rate, and expression of neuroﬁ-
lament-M (NF-M; an early marker of neuronal differentiation)
were assessed. Fig. 1a demonstrates a change in morphologycharacteristic of differentiated neurons as early as 48 h with ATRA
treatment. The initiation of neurite formation (arrows) supports an
early effect of ATRA to promote differentiation. Images captured
after 2 weeks of continuous ATRA treatment (10 mM) display fully
differentiated cells with very prominent neurite processes (ar-
rows). These early changes in morphology were accompanied by
increased expression of NF-M upon ATRA treatment (Fig. 1b). Cell
numbers were also decreased in ATRA treated cells, with sig-
niﬁcant changes observed at 96 h (Fig. 1c), subsequent to increased
NF-M expression.
3.2. ATRA modulates DCFH2 and MitoSOX oxidation as well as in-
duction of MnSOD
Although previous reports have investigated the generation of
ROS in neuroblastoma cell lines (including a subclone of the SK-N-
SH's) [10,27], the role of either O2 or H2O2 in ATRA-induced
differentiation of this cancer cell type is unknown. Our previous
publication demonstrates a signiﬁcant up-regulation of MnSOD
activity with 72 h ATRA treatment of SK-N-SH cells [17]. The
MnSOD enzyme scavenges O2 at the mitochondrial level;
yielding hydrogen peroxide as the product (H2O2). Therefore,
evaluation with both MitoSOX (an indicator of mitochondrial
O2) and CM-H2DCFDA (an indicator of intracellular H2O2) was
performed to assess steady-state levels of ROS. Treatment with
ATRA signiﬁcantly increased MitoSOX oxidation in comparison to
controls at all time points (Fig. 2); with a major peak seen at 48 h,
preceding the ATRA-mediated increase in MnSOD activity in these
cells. Parallel cultures were incubated with rotenone (1–200 mM as
a positive control), and exhibited a concentration-dependent in-
crease in MitoSOX oxidation (data not shown).
As MitoSOX ﬂuorescence returned towards baseline levels (72–
96 h); ATRA signiﬁcantly increased DCFH2 oxidation at 96 h. Hy-
drogen peroxide was used as a positive control and also increased
DCFH2 oxidation over that of control cells (data not shown). Since
DCFH2 oxidation is not speciﬁc for H2O2 (i.e. peroxynitrite) [22],
polyethylene glycol-conjugated catalase (PEG-Cat-100 U/mL) was
used to conﬁrm the increase in ﬂuorescence was indicative of
changes in steady-state levels of H2O2. Pretreatment of cells with
PEG-Cat signiﬁcantly attenuated H2O2-induced (Fig. 3a) as well as
ATRA-induced (Fig. 3b) increases in DCFH2 oxidation, supporting
the conclusion that the increased dye oxidation seen at 96 h of
ATRA treatment was caused by H2O2.
3.3. ATRA effects on glutathione (GSH) levels; glutathione peroxidase
Fig. 3. PegCat-mediated reductions in DCFH2 oxidation. DCF oxidation was as-
sessed in SK-N-SH cells after treatment with (A) H2O2 (0.1 μM, 20 min, n¼4) or
(B) ATRA (10 μM, 96 h, n¼3). Cells were pretreated with PegCat (100 U/ml) for 3 h
prior to DCFH2 (2.5 μM) incubation. *po0.05 vs. CON (-)PegCat; †po0.05 vs. *.
One-way ANOVA; Student-Newman–Keuls. Results are expressed as fold changes
vs. CON (-)PegCat7SEM.
Fig. 4. ATRA decreased glutathione (GSH) levels. (A) Reduced GSH and
(B) glutathione disulﬁde (%GSSG) levels were assessed in SK-N-SH cells after
treatment with ATRA (10 μM) after 24–96 h. n¼7. *po0.05 vs. CON per time point.
T-test performed for each time point. Results are expressed as fold change vs. CON
per time point7SEM.
Fig. 5. ATRA did not signiﬁcantly alter glutathione peroxidase (GPx) activity. Glu-
tathione peroxidase (GPx) activity in SK-N-SH cells after treatment with ATRA
(10 μM) after 24 (n¼5), 48, 72 and 96 (n¼9) hrs. T-test performed for each time
point. One- way ANOVA amongst CON and ATRA. Results are expressed as GPx
activity (munits/mg protein)7SEM.
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Given that ATRA increased DCFH2 oxidation, the subsequent
antioxidant response by peroxide scavengers such as glutathione
(GSH), glutathione peroxidase (GPx), and catalase was determined.
GSH levels were signiﬁcantly decreased following ATRA treatment
in comparison to non-treated cells at all time points (Fig. 4a).
Furthermore, oxidized GSH (%GSSG) was signiﬁcantly increased in
the presence of ATRA at 48 h (Fig. 4b). GSH is a substrate used by
GPx to catalyze the degradation of H2O2. However, ATRA treatment
of SK-N-SH cells did not alter GPx activity in comparison to con-
trols at any time point (Fig. 5). ATRA signiﬁcantly increased cata-
lase activity at 24 h; but this subsided to levels comparable to
control cells by 48–96 h (Fig. 6). The signiﬁcant increase found in
GPx and catalase activity in non-treated cells during the course of
the experiment is consistent with previous reports demonstrating
the ability of cells to increase activity of these enzymes as a
function of time and cell density when cultured in vitro [28]. Both
GPx and catalase activity follow the same trend as the control cells
over time when treated with ATRA. Altogether, increased MnSOD,
increased DCFH2 oxidation, decreased GSH, and the lack of either
GPx or catalase upregulation correlated with elevated H2O2 at the
96 h time point of ATRA treatment.
3.4. Reducing MnSOD activity decreased DCFH2 oxidation and in-
creased MitoSOX oxidation at 96 h
Several studies have investigated ROS production andantioxidant expression for differentiated neural cell types
[10,27,29,41], but few provide a time-course analysis of these ef-
fects during the early process of differentiation. Our next step was
to determine the effect of altering steady-state levels of ROS by
reducing MnSOD activity. A signiﬁcant increase in MnSOD activity
was noted when treating SK-N-SH cells with ATRA for 72 and 96 h
(Fig. 7). In both control and ATRA-treated cells, activity was sig-
niﬁcantly decreased in the presence of SOD2 siRNA versus Ctrl
siRNA for 48, 72 and 96 h. MitoSOX oxidation was also measured
Fig. 6. ATRA's effects on catalase activity. Catalase activity of SK-N-SH cells after
treatment with ATRA (10 μM) for 24, 48, 72, and 96 h. n¼6. *po0.05 vs. CON at
respective time point. T-test performed for each time point. †po0.05 vs. CON 24 h.
One way ANOVA amongst CON. Results are expressed as mkUnits/mg
protein7SEM.
Fig. 7. MnSOD activity decreased with SOD2 siRNA treatment.MnSOD activity was
assessed in SK-N-SH cells after treatment with ATRA (10 μM) for 24, 48, 72, and
96 h. 24: n¼3; 48–96: n¼4. *po0.05 vs. CON at respective time point.. †po0.05 vs.
* Two-way ANOVA per timepoint; Student-Newman–Keuls. Results are expressed
as fold change vs. CON7SEM per timepoint.
Fig. 8. Reducing MnSOD activity increased MitoSOX and decreased DCFH2 oxida-
tion at 96 h of exposure to ATRA. MitoSOX (A) and DCFH2 (B) oxidation in SK-N-SH
cells after incubation with either a control vector (Ctrl-siRNA) or one targeting the
MnSOD gene (SOD2-siRNA) and subsequent treatment with ATRA (10 μM). DCF:
n¼3, MitoSOX: n¼8. MitoSOX: *po0.01 vs. CON-Ctrl siRNA; †po0.05 vs. CON-
SOD2 siRNA; ‡po0.05 vs †. T-test. DCF: *po0.001 vs. CON-Ctrl siRNA; †po0.05 vs.
CON-SOD2 siRNA; ‡po0.05 vs *. One way ANOVA; Student-Newman–Keuls. Results
are expressed as fold changes vs. Mock-CON (DCF: not shown) or CON-Ctrl siRNA
(MitoSOX)7SEM.
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levels of O2 (Fig. 8a). Again, at 24 h, ATRA signiﬁcantly increased
MitoSOX oxidation versus control cells in the presence of SOD2
siRNA. At 96 h, MitoSOX oxidation in both Ctrl and SOD2 siRNA
transfected cells was signiﬁcantly increased by ATRA in compar-
ison to controls. Furthermore, there was a signiﬁcant increase in
MitoSOX oxidation when comparing ATRA-SOD2 siRNA to ATRA-
Ctrl siRNA. In contrast, at 96 h, the reduction of MitoSOX oxidation
towards baseline levels in control cells with ATRA treatment is
apparent. ATRA-stimulated DCFH2 oxidation was signiﬁcantly at-
tenuated when MnSOD activity was reduced with siRNA (SOD2
siRNA) (Fig. 8b). These results suggest that MnSOD may modulate
increases in steady-state levels of H2O2 during ATRA treatment at
96 h. These ﬁndings support the conclusion that a reduction in
MnSOD activity caused by siRNA treatment of neuroblastoma cells
caused an increase in steady-state levels of O2 at 48–96 h.
3.5. Reducing MnSOD activity enhanced expression of NF-M at 48 h
but led to diminished levels of NF-M at 96 h of treatment with ATRA
Having identiﬁed 1) an increase in MnSOD that correlated with
increased levels of the neuronal differentiation marker NF-M
(Fig. 1b), and 2) similar changes in steady-state levels of O2 andH2O2 caused by reducing MnSOD activity (Fig. 8a and b); we next
determined if altering MnSOD inﬂuenced the expression of NF-M.
At 48 h of treatment with 10 uM ATRA, immuno-reactive NF-M
increased prior to the signiﬁcant induction of MnSOD activity at
72 h (Fig. 9a and b). Furthermore, inhibiting MnSOD activity with
siRNA not only enhanced ATRA-induced expression of NF-M
(ATRA-SOD2 siRNA), but it also signiﬁcantly increased its expres-
sion over that of the cells receiving only the control siRNA vector
(CON-Ctrl siRNA) at 48 h. This effect was diminished at 96 h.
Fig. 9a and c demonstrates the signiﬁcant increase in MnSOD
protein expression in the presence of ATRA at 72 and 96 h, and the
signiﬁcant reduction of this antioxidant enzyme in the presence of
the SOD2 siRNA at 48 and 96 h. In agreement with protein ex-
pression, MnSOD activity was also reduced to 50% of normal
values at each time point (Fig. 6a – 96 h). Furthermore, the re-
duction in DCFH2 oxidation (Fig. 7a) and increase in MitoSOX
oxidation (Fig. 7b) in the presence of SOD2 siRNA were consistent
with decreases in MnSOD activity. These data suggest that MnSOD
is not critical for initiating the differentiation process by modula-
tion of NF-M expression at 48 h in the SK-N-SH cells but that su-
peroxide is the inducer of these biological effects.
3.6. PegCat treatment inﬂuenced the expression of NF-M at 96 h of
Fig. 9. Reducing MnSOD activity enhanced NF-M expression at 48 and 72 h but
diminished it at 96 h. Western Blot analysis of (A,B) NF-M and MnSOD (A,C) in SK-
N-SH cells after incubation with either a control vector (Ctrl siRNA) or one targeting
the MnSOD gene (SOD2 siRNA) and subsequent treatment with ATRA (10 μM) for
48, 72, and 96 h. n¼6. *po0.05 vs. CON-Ctrl siRNA per time point, †po0.05 vs *.
Kruskal–Wallis one way ANOVA on ranks. Results are expressed as fold changes vs.
CON-Ctrl siRNA per time point7SEM.
Fig. 10. PegCat treatment inﬂuenced NF-M expression in a similar manner to re-
ducing MnSOD activity at 96 h of ATRA. (A,B) Western Blot analysis of neuroﬁla-
ment M (NF-M) expression in SK-N-SH cells after 24 h pre-incubation with PegCat
(100 U/mL) and subsequent treatment with ATRA (10 μM) for 48, 72, and 96 h.
n¼6. *po0.05, signiﬁcant difference vs. CON (-)PegCat; Kruskal–Wallis one way
ANOVA on ranks. †po0.05, signiﬁcant difference vs. CON (-)PegCat; One way AN-
OVA; Student-Newman-Keuls. Results are expressed as fold changes vs. CON (-)
PegCat per time point7SEM.
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To evaluate the role of H2O2 in ATRA-mediated induction of NF-
M expression, we incubated the cells continuously in the presence
of PegCat for 0–96 h. Western blot analysis demonstrated that
PegCat treatment inﬂuenced the expression of NF-M in a similar
manner as did the SOD2 siRNA construct (Fig. 10a and b). Although
there was no signiﬁcant enhancement of NF-M expression at 48 h
by PegCat treatment, it is apparent that any signiﬁcant up-reg-
ulation of NF-M expression by ATRA was lost by 96 h in the pre-
sence of PEG-Cat. These ﬁndings parallel those found by reducing
MnSOD activity at 96 h of ATRA treatment.4. Discussion
Many studies have demonstrated that retinoid-induced neu-
ronal differentiation results in increased steady-state levels of re-
active oxygen species (ROS) as well as altered levels of antioxidant
enzymes [12,18,27,35]. About 1–3% of oxygen consumed by thebody is converted into ROS; three of the most prominent being
superoxide anion (O2), hydrogen peroxide (H2O2) and hydroxyl
radical (OH) [38]. Therefore, cells have developed a means to limit
excess accumulation of ROS by induction of antioxidant defense
systems (i.e. superoxide dismutases, catalase, glutathione perox-
idase, glutathione) [6]. We have previously reported a time-de-
pendent ATRA-mediated increase in manganese superoxide dis-
mutase (MnSOD) mRNA, protein and activity in the SK-N-SH cells
[17]; and the current study identiﬁes a rise in ROS levels that likely
initiates this adaptive response by MnSOD. The aims of this study
were to determine the role of ROS and/or MnSOD activity in ATRA-
mediated differentiation.
In PC12 cells, generation of O2 via xanthine/xanthine oxidase
induces neurite outgrowth, which is characteristic of differentia-
tion of this and other neuronal cell types [14]. Kamata and others
suggest that ROS (i.e. H2O2) mediate the actions of nerve growth
factor (NGF) to promote neuron survival and axonal regeneration
also in PC12 cells [16,41]. We now provide a time-course analysis
of ROS generation and antioxidant expression in differentiating
SK-N-SH neuroblastoma cells treated with 10 uM ATRA (Figs. 2, 4–
7).
MnSOD is a mitochondrial enzyme upregulated in the presence
of O2 [8,31], and has been shown by Fridovich and others to be
necessary for survival in oxygen-metabolizing cells [25]. Homo-
zygous MnSOD null mice die within the ﬁrst 10–30 days of life due
to dilated cardiomyopathy and neurodegeneration [23,24]. This
essential antioxidant enzyme not only protects against ROS accu-
mulation, but is important in the process of differentiation in some
cell types [5,40]. Transfection of human MnSOD cDNA into mouse
10T1/2 embryonic cells enhanced 5-azacytidine mediated differ-
entiation [40]. Differentiation of IMR-32 neuroblastoma cells also
resulted in an increase in MnSOD activity, which correlated with
an increase in ROS [10].
Human neuroblastoma cell lines (i.e., SK-N-SH) are composed
of three distinct cell types (epithelial, neuronal, and intermediate)
and are sensitive to retinoid-induced growth inhibition and for-
mation of neurite extensions. Sidell et al. demonstrate that growth
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decreased malignant phenotype [37]. We conﬁrm these observa-
tions by identifying NF-M as an early neuronal differentiation
marker whose protein expression increases two days prior to
growth suppression by ATRA. In parallel to these changes, ATRA
caused the upregulation of the essential mitochondrial antioxidant
enzyme, MnSOD. The importance of the mitochondria in differ-
entiation is supported in other neuronal models. In HN9.10e hip-
pocampal neuroblasts, retinoic acid-induced neurite formation
resulted in remodeling of the mitochondrial network, fusion of
mitochondria and collective distribution throughout the neurites,
and an increase in mitochondrial potential [45]. It is well estab-
lished that there is a strong correlation between an increase in
mitochondrial membrane potential and the production of ROS
[19,42]. Schneider et al. support this ﬁnding by showing an in-
crease in mitochondrial membrane potential during ATRA-induced
differentiation of SH-SY-5Y cells (a subclone of the SK-N-SH po-
pulation) [35]. Furthermore, they also demonstrated distribution
of the mitochondrial network throughout the neurites and, in
accordance with our ﬁndings, reported increased MnSOD
expression.
Using an indicator of steady-state levels of mitochondrial O2 ,
MitoSOX oxidation was found to increase in the presence of ATRA
treatment. Leukocytes also produce ROS, in particular O2 , which
is correlated with their differentiation [7,46]. We observed that the
increase in MitoSOX oxidation in the SK-N-SH cells is sustained for
at least 96 h. However, a closer examination of the changes in
steady-state levels of MitoSOX oxidation over time suggests that
O2 levels return to baseline levels at the same time point (72 h)
that a signiﬁcant increase in MnSOD activity occurred following
treatment with ATRA [17]. The increase in DCFH2 oxidation and
subsequent attenuation by PegCat treatment at 96 h further sug-
gests that production of H2O2 parallels an increase in MnSOD ac-
tivity. These studies provide a time-course analysis of both steady-
state levels of O2 and H2O2 that appears to be coordinately
regulated by induction of MnSOD activity. Furthermore, speciﬁ-
cally identifying that abrogation of H2O2 limits the expression of
NF-M at 96 h of treatment with ATRA supports the hypothesis that
H2O2 is as an important signaling molecule in this classic model of
neuronal differentiation.
In order to get a more complete view of the redox status of the
SK-N-SH cells in the presence of ATRA, we also assessed GSH
content, GPx and catalase activity. Each of these endogenous an-
tioxidant defense systems is integral in the handling of H2O2.
Many studies also implicate GSH as an essential mediator of cel-
lular proliferation [32,33]. In this study, we made the novel ﬁnding
that ATRA signiﬁcantly reduces GSH levels in neuroblastoma cells.
Although others show that cAMP treatment of the IMR-32 neu-
roblastoma cell line resulted in a reduction of GSH, which was
enhanced by ATRA, there was no signiﬁcant change in GSH levels
in the presence of ATRA alone [4]. The GPx enzyme was also as-
sessed due to the fact that it uses GSH as a substrate for scavenging
peroxides. However, we discovered no signiﬁcant change in GPx
activity in the presence of ATRA at any time point (24–96 h). These
data implicate that ATRA functions by a different mechanism to
decrease GSH.
Decreased catalase activity is associated with increased differ-
entiation of IMR-32 neuroblastoma cells [10], and addition of
catalase decreased NGF-stimulated neuronal differentiation of
PC12 cells [41]. In the current study, we demonstrated an initial
increase in catalase activity by ATRA within 24 h. Differentiation of
Neuro2A mouse neuroblastoma cells with ATRA has been shown
to increase catalase activity by a similar magnitude [36]. A lack of
increased catalase activity at 96 h in the current study suggests
that either H2O2 is not scavenged or that there are insufﬁcient
levels to elicit catalase activity. Accordingly, there is growingevidence for the role of H2O2 to be a key signaling molecule and
regulate gene expression in many cellular models (as reviewed in
[1]).
We have demonstrated that ATRA up-regulates the expression
of NMDAR1 [17] and NF-M (at 48 h) prior to a signiﬁcant increase
in MnSOD activity (at 72 h). This suggests that MnSOD is not es-
sential to initiate differentiation. However, an interesting ﬁnding is
that a reduction of MnSOD activity enhanced NF-M expression at
48 h. Rather than directly affecting target proteins, slight changes
in MnSOD may alter the redox status (i.e. through altering steady-
state levels of O2 and H2O2) to inﬂuence, for example, the
polymerization of NF-M. The stability and structure of inter-
mediate ﬁlament proteins such as NF-M have been shown to be
susceptible to damage by oxidative stress [13]. The relative ratios
of these ROS may therefore affect NF-M stability and function.
Attenuation of ATRA-induced NF-M expression by reducing
MnSOD at 96 h suggests a role for MnSOD (and possibly H2O2) in
differentiation at the later time point. Additionally, the current
study investigates relative changes in ROS (O2 and H2O2) during
the differentiation process, whereas many studies examine one
time point and may overlook the unique roles each of these ROS
play as the differentiation process proceeds. The generation of
H2O2 by MnSOD might function to further the differentiation
process at 96 h and beyond. Otherwise, considering that MnSOD is
well known to promote cell survival, differentiated cells (at 48 h)
may subsequently undergo apoptosis (at 96 h). Long-term retinoid
treatment of the SK-N-SH cell line, comprised of both epithelial (S-
type) and neuronal (N-type) cell types, induces death in the S-type
and differentiation of the N-type [26]. Therefore, in this model,
future work should investigate if the N-type cell population is
subject to apoptosis by reducing MnSOD activity. These ﬁndings
would hold potential to improve retinoid therapy by augmenting
the differentiation process earlier and subjecting differentiated
cells to apoptosis by manipulations of SOD activity.5. Conclusions
Reactive oxygen species have received a lot of attention in the
past few decades because they are generated by all aerobic or-
ganisms and are known to be involved in a variety of cellular re-
sponses, both harmful and beneﬁcial. Moreover, the various anti-
oxidant defense systems within cells have been intensely studied
in light of their capacities to inﬂuence gene expression in many in
vitro and in vivo models. Although the generation of ROS is often
associated with damaging effects, they also play an essential role
in key signal transduction pathways that are involved in the pro-
cesses of cellular proliferation, apoptosis, cell cycle arrest, and
differentiation (as reviewed in [43]). Here we closely examine the
redox status of the SK-N-SH cells as determined by steady-state
levels of dye oxidation and cellular antioxidant expression. We
have identiﬁed H2O2 as a potential signaling molecule to promote
ATRA-mediated neuronal differentiation. Our previous work de-
monstrated NF-κB regulation of both MnSOD and differentiation;
therefore, current ﬁndings compel us to investigate if this is
mediated by H2O2 generation. We hypothesized that reducing
MnSOD activity early on in retinoid treatments may stimulate
expression of neuronal differentiation markers in neuroblastoma
cells. If MnSOD-mediated H2O2 generation is important to pro-
mote differentiation at the later time points in therapy, early in-
terventions preventing H2O2 degradation or inhibiting SOD activ-
ity could provide potential beneﬁts for improving responses to
retinoid based neuroblastoma therapies.
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